Never Run Out Of Buyers To Sell To.

VALANX has built GoldenSite, a site-specific conjugation platform that places ADC payloads in structurally shielded positions on the antibody, delivering significantly reduced off-target interaction while preserving and enhancing efficacy. Using GoldenSite, we are developing a LIV-1 targeting, differentiated ADC intended to treat metastatic triple-negative-breast cancer.
Annual Revenue$10M to $25M
Estimated OwnershipPrivateBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.